Catalent Invests $200 Million to Expand Biologics Capacity and Capabilities

Catalent Invests $200 Million to Expand Biologics Capacity and Capabilities SOMERSET, N.J. – January 7, 2019— Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it has commenced a $200 million capital investment in its Biologics business to expand drug […]

Read More